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Abstract Chronic traumatic encephalopathy (CTE) is a
neurodegeneration characterized by the abnormal accumulation of hyperphosphorylated tau protein within the brain.
Like many other neurodegenerative conditions, at present,
CTE can only be definitively diagnosed by post-mortem
examination of brain tissue. As the first part of a series of
consensus panels funded by the NINDS/NIBIB to define
the neuropathological criteria for CTE, preliminary neuropathological criteria were used by 7 neuropathologists to
blindly evaluate 25 cases of various tauopathies, including
The members representing TBI/CTE group are listed in the
Appendix.
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CTE, Alzheimer’s disease, progressive supranuclear palsy,
argyrophilic grain disease, corticobasal degeneration, primary age-related tauopathy, and parkinsonism dementia
complex of Guam. The results demonstrated that there
was good agreement among the neuropathologists who
reviewed the cases (Cohen’s kappa, 0.67) and even better
agreement between reviewers and the diagnosis of CTE
(Cohen’s kappa, 0.78). Based on these results, the panel
defined the pathognomonic lesion of CTE as an accumulation of abnormal hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels
at the depths of cortical sulci and in an irregular pattern.
The group also defined supportive but non-specific p-tauimmunoreactive features of CTE as: pretangles and NFTs
affecting superficial layers (layers II–III) of cerebral cortex;
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pretangles, NFTs or extracellular tangles in CA2 and pretangles and proximal dendritic swellings in CA4 of the
hippocampus; neuronal and astrocytic aggregates in subcortical nuclei; thorn-shaped astrocytes at the glial limitans
of the subpial and periventricular regions; and large grainlike and dot-like structures. Supportive non-p-tau pathologies include TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus,
anteromedial temporal cortex and amygdala. The panel also
recommended a minimum blocking and staining scheme
for pathological evaluation and made recommendations
for future study. This study provides the first step towards
the development of validated neuropathological criteria
for CTE and will pave the way towards future clinical and
mechanistic studies.
Keywords Chronic traumatic encephalopathy ·
Traumatic brain injury · Tauopathy · Brain trauma ·
Neurodegenerative disorders

Introduction
In 1928, the pathologist and medical examiner, Harrison
Stanford Martland, introduced the term ‘punch-drunk’ to
describe the clinical features of a distinct neuropsychiatric syndrome that affected boxers [26]; a condition that
later came to be known as ‘dementia pugilistica’ [33]. Case
reports and small series describing the neuropathologic features of the condition appeared in the 1950s and 1960s [3,
6, 16, 27, 35, 41]. Although the histological techniques varied, the most common pathological findings were cerebral
atrophy, neuronal loss, gliosis and argyrophilic neurofibrillary tangles. In the seminal 1973 monograph on the clinicopathological features of dementia pugilistica in 15 former male boxers, Corsellis, Bruton, and Freeman-Browne
described cerebral atrophy, enlargement of the lateral and
third ventricles, thinning of the corpus callosum, cavum
13

Department of Neuropathology, University of Glasgow
Institute of Neuroscience and Psychology and Queen
Elizabeth University Hospital, 1345 Govan Road,
Glasgow G51 4TF, UK

14

Department of Biostatistics, Boston University School
of Public Health, 801 Massachusetts Avenue, Boston MA,
02118, USA

15

Department of Pathology, Fishberg Department
of Neuroscience, Friedman Brain Institute, Ronald M. Loeb
Center for Alzheimer’s Disease, Icahn School of Medicine
at Mount Sinai School, One Gustave L. Levy Place, New
York, NY 10029, USA

16

Department of Rehabilitation Medicine, Icahn School
of Medicine at Mount Sinai, 3 East 101st Street, New York,
NY 10029, USA

13

septum pellucidum with fenestrations, cerebellar scarring,
and argyrophilic neurofibrillary degeneration using cresyl
violet and Von Braunmühl’s silver stains [5]. Subsequent
re-examination of Corsellis’ original series of boxers and
additional cases using beta-amyloid (Aβ) immunohistochemistry determined that 95 % of CTE cases showed
widespread diffuse Aβ deposits [43, 46].
Over the following decades, it was recognized that the
condition affected men and women with a broad range of
exposure to brain trauma, including physical abuse [42],
head-banging [13, 18], poorly controlled epilepsy, “dwarfthrowing” [48], and rugby1 [13]. Eventually, the term
“chronic traumatic encephalopathy” or “CTE”, introduced
by Critchley in 1949 [8], became the preferred designation
for the condition.
Coincident with the use of more refined methodology, the early pathology of CTE was reported in several
young subjects [13, 14, 18]. Hof reported a single case of
repetitive head-banging in a young autistic patient with
numerous perivascular clusters of thioflavin and Gallyaspositive neurofibrillary tangles (NFTs) and neurites at the
depths of the cerebral sulci and in the superficial layers of
the inferior temporal, entorhinal and perirhinal cortices in
the absence of Aβ plaques [18]. Hof and colleagues also
quantitatively demonstrated the preferential distribution of
the NFTs in superficial layers II and III in CTE, a laminar predilection characteristic of two other environmentally acquired tauopathies, post-encephalitic parkinsonism
and Guamanian parkinsonism dementia complex (GPDC),
but not found in Alzheimer’s disease (AD) [19]. Geddes
and colleagues further described argyrophilic, hyperphosphorylated tau (p-tau) immunopositive neocortical NFTs
and neuropil threads strikingly arranged in groups around
small cortical blood vessels, in addition to diffuse granular
cytoplasmic immunopositivity in some neurons [13]. Geddes also noted that the topography of the p-tau pathology
principally involved the depths of sulci and that there was
no Aß deposition in the 5 young cases that formed the basis
of their manuscript [13].
Omalu and colleagues were the first to report CTE in a
professional American football player [38, 39] and a professional wrestler [37]. Recent neuropathological studies
have identified CTE in athletes who played soccer, baseball, ice hockey and rugby, as well as in military personnel exposed to explosive blast [15, 29, 31, 32, 36, 45].
P-tau pathology, with some features of CTE, has also been

1

Although often referred to as a soccer player, the young subject
with CTE described by Geddes et al. 1999 as the “keen amateur footballer who frequently “headed” the ball while playing” [13], was an
amateur rugby player (personal communication, T. Revesz).
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described following exposure to single moderate or severe
traumatic brain injury, together with Aβ plaques [20, 44].
In 2013, McKee and colleagues described a spectrum of
p-tau pathology in 68 male subjects with a history of exposure to repetitive brain trauma with neuropathological evidence of CTE, ranging in age from 17 to 98 years (mean
59.5 years). In young subjects with the mildest forms of
CTE, focal perivascular epicenters of NFTs and astrocytic
tangles (ATs) were found clustered at the depths of the
cortical sulci; in subjects with severe disease, a profound
tauopathy involved widespread brain regions [32]. Other
abnormalities encountered in advanced disease included
abnormal deposits of phosphorylated TAR DNA-binding
protein of 43 kDa (TDP-43) protein that occasionally colocalized with p-tau, varying degrees of Aβ pathology,
axonal dystrophy and neuroinflammation [30, 32]. Based
on these findings, preliminary criteria for the neuropathological diagnosis of CTE were proposed, as follows:
1. Perivascular foci of p-tau immunoreactive NFTs and
ATs in the neocortex
2. Irregular distribution of p-tau immunoreactive NFTs
and ATs at the depths of cerebral sulci
3. NFTs in the cerebral cortex located preferentially in
the superficial layers (often most pronounced in temporal cortex)
4. Supportive, non-diagnostic features: Clusters of subpial ATs in the cerebral cortex, most pronounced at
the sulcal depths.
In March 2013, the National Institutes of Health (NIH),
supported by the Foundation for NIH’s Sports Health
Research Program with funding from the National Football
League (NFL), launched a major effort to define the neuropathological characteristics of CTE. Two projects were
initiated on the neuropathology of CTE and the delayed
effects of traumatic brain injury. One of the initial objectives was to convene a consensus meeting to define the
neuropathological criteria for the diagnosis of CTE. The
primary objective for the first meeting was to determine
whether CTE was a distinctive tauopathy that could be reliably distinguished from other tauopathies using the preliminary criteria. The study design was modeled after previous
successful NIH-sponsored consensus conferences for other
tauopathies, specifically progressive supranuclear palsy
(PSP) and corticobasal degeneration (CBD) [10, 17, 25].

Materials and methods
Individuals not directly involved in the pathological evaluation (ACM, VEA, KFB, JFC) selected 25 cases of the
various tauopathies. The selected cases were considered to
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be representative of the disease and of at least moderate
disease severity. The cases included 10 recently acquired
cases of suspected CTE that were donated as part of the
NINDs-funded traumatic brain injury (TBI) brain bank at
Boston University School of Medicine (BUSM), including
7 cases with Aβ plaques and 3 cases without Aß plaques.
Five cases of AD, Braak stage V-VI, 2 cases of PSP and
2 cases of CBD were selected from the Alzheimer’s Disease Center (ADC) brain bank at BUSM. Two cases of
GPDC and 2 cases of argyrophilic grain disease (AGD)
were selected from the Alzheimer’s Disease Research
Center (ADRC) brain bank at Mayo Clinic-Jacksonville,
and 2 cases of primary age-related tauopathy (PART) were
selected from the ADRC brain bank at Columbia University. Paraffin-embedded tissue blocks from 12 brain
regions from each case were sent to the TBI Brain Bank
at BUSM for uniform processing, staining and immunohistochemistry (IHC) (Table 1); 2 of the selected cases
were missing the superior temporal block. Sections were
stained with Luxol fast blue counterstained with hematoxylin and eosin (LHE) and Bielschowsky silver impregnation; IHC was performed using anti-Aβ42 (Aß 1-42, EMD
Millipore, 1:2000, pretreated with 88 % formic acid for
2 min; or Aβ-4G8, Bio Legend, 1:100,000, pretreated with
formic acid); anti-p-tau (AT8, Thermo Fisher Scientific/
Table 1  Brain regions evaluated in the case review
Brain region

Stains/IHC
LHE AT8 Aβ42 TDP43 BIEL

Superior frontal (BA 8, 9)
X
Dorsolateral superior frontal (BA X
45, 46)

X
X

Caudate nucleus, nucleus accum- X
bens, putamen

X

Temporal pole (BA 38)
X
Superior temporal gyrus (BA 20, X
21,22)

X
X

Amygdala, with entorhinal cortex X
(BA 28)

X

Hippocampus and lateral genicu- X
late nucleus

X

Thalamus and mammillary body X

X

Cerebellum with dentate nucleus X

X

X

X

X

X

X

Digitized images of the following microscopic slides were provided
to the evaluating neuropathologists on 25 cases of tauopathies including AD, AGD, CBD, CTE, GPDC, PART and PSP. The slides were all
uniformly processed by a single laboratory
Aβ Beta-amyloid, AD Alzheimer’s disease, AGD Argyrophilic grain
disease, BA Brodmann area, BIEL Bielschowsky’s silver method,
CTE Chronic traumatic encephalopathy, GPDC Guamanian Parkinson’s dementia complex, LHE Luxol fast blue, counterstained with
hematoxylin and eosin, PART Primary age-related tauopathy, PSP
Progressive supranuclear palsy
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Pierce, 1:2000, pretreated with formic acid) and anti-pTDP-43 (Anti-TDP-43, phospho, 1:2000, pretreated with
formic acid) for a total of 27 slides per case (25 slides in
2 cases). An individual blinded to the origin and identity
of the cases (KFB) scanned the 671 glass pathology slides
into digital images at the Mayo Clinic Jacksonville using
an Aperio scanner (Leica Biosystems, Buffalo Grove, IL).
The digitized images were organized into folders labeled
with only the case number (#1-25), brain region, stain and
IHC and provided to the evaluating neuropathologists on
portable hard drives as well as on an online slide-hosting
website (Leica Biosystems-Aperio). No clinical or demographic information was provided to the evaluating neuropathologists—including no information regarding the
subjects’ age, gender, clinical symptoms, diagnosis or
athletic exposure. No information was supplied regarding the gross neuropathological features of the brains. The
neuropathologists were given a tauopathy criteria guide
that provided the provisional criteria for CTE [32] as well
as published criteria for the other tauopathies (See supplementary material for full tauopathy criteria guide) [4,
7, 11, 21, 25, 34, 40, 47]. Although the neuropathologists
knew that the selected cases represented presumptive CTE,
AD, PSP, CBD, AGD, PART, and GPDC, they did not
know how many cases representing each diagnosis were to
be evaluated.
Seven neuropathologists with experience in neurodegenerative diseases, including the tauopathies, participated in
the evaluation of the digitized images (NJC, DWD, RDF,
CDK, DPP, TDS, JPV). The neuropathologists evaluated
the cases independently, at their own pace, and completed
an evaluation form that included the pathological diagnosis
and a 4-scale level of certainty (1, unsure; 2, possible; 3,
probable; 4, definite). After the initial evaluations were sent
to BUSM for analysis, the evaluator was provided the gross
neuropathological findings and clinical summaries for each
case, and asked to reevaluate the diagnosis and provide a
second level of conviction. The results of all evaluations
were analyzed prior to the face-to-face meeting held on
February 25–26, 2015.
Statistical analysis
To evaluate the agreement among the neuropathologists
who reviewed the cases, two sets of Cohen’s kappa statistics were calculated. The first kappa coefficient measured
the agreement among the overall neuropathological diagnoses; the second kappa coefficient measured the agreement
among neuropathologists regarding the specific diagnosis
of CTE. The overall kappa coefficient combines the neuropathologist-level estimates of kappa into an overall estimate of the common agreement. Kappa values of 0.81–1.0
indicate very good agreement, kappa values of 0.61–0.80
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show good agreement, while kappa values of 0.41–0.60
indicate moderate agreement [12]. All statistical analyses
were done using SAS 9.4 (SAS Institute Inc., Cary, North
Carolina, USA) software.
At the face-to-face consensus meeting, a larger panel
that included ACM2, WS,2 IL, WAG and members of the
NINDs TBI/CTE group reviewed the results of the neuropathological evaluations, digitized images and glass pathology slides and discussed the cases as a group. Discussions
led to refinements in the neuropathological criteria for
CTE, as well as “best practice” recommendations for neuropathologists examining brains for evidence of CTE.

Results
There was good agreement regarding the overall neuropathological diagnosis of all 25 cases (Cohen’s kappa,
0.67), and even better agreement regarding the specific
diagnosis of CTE (Cohen’s kappa, 0.78), using the proposed criteria. In evaluating the 10 cases submitted with the
presumptive diagnosis of CTE (Supplementary Table 1),
64 of the 70 reviewers responses (91.4 %) indicated CTE
as the diagnosis. There was a significant decrease of errors
that paralleled the sequence of cases evaluated. The log of
the expected errors significantly decreased by 0.43 for each
case of CTE reviewed (p value = 0.024). There were common additions to the CTE diagnosis, including “Changes
of Alzheimer’s disease” (ADC) and AD in the cases with
Aß plaques (cases #4–10). Other co-morbid diagnoses
included hippocampal sclerosis (HS), AGD and PART. In
the 15 other tauopathy cases (cases submitted for review
with diagnoses other than CTE) (Supplementary Table 2),
the reviewers generally agreed with the submission diagnoses of AD (97.1 % of responses), CBD (92.8 %), and PART
(78.5 %); however, there were frequent discrepancies in
cases with the presumptive diagnoses of PSP, AGD and
GPDC (Supplementary Table 2). The evaluators reported
a significantly increased degree of certainty (t test = 4.36,
p value <0.001) in the diagnosis of CTE from an overall
mean of 3.1 in a 4-point scale of conviction (1, unsure; 2,
possible; 3, probable; 4, definite) to a mean of 3.7 after the
gross neuropathological features and clinical features of
the cases were provided to the evaluator. Three initial diagnoses of non-CTE were changed to CTE and 9 diagnoses
of co-morbid CTE in non-CTE cases were changed to no
CTE after revealing the clinical and gross neuropathological features.

2

Neuropathologist present at the face-to-face panel discussion, but
did not participate in the slide evaluations.
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Diagnostic neuropathological features of CTE
The group defined a neuropathological lesion specific to
CTE that distinguished the disorder from other tauopathies. The pathognomonic lesion of CTE consists of p-tau
aggregates in neurons, astrocytes, and cell processes
around small vessels in an irregular pattern at the depths
of the cortical sulci (Figs. 1, 2; Table 2). The group also
noted that the distinctively irregular spatial pattern of
p-tau in CTE was often visible with low-power inspection (Fig. 1). Although other abnormalities in p-tau were
also found, especially in the more severely affected
brains, the pathognomonic lesion was distinct and not
found in the other degenerative tauopathies (Fig. 2). In
addition, the group observed frequent evidence of other
pathologies in CTE, including TDP-43-immunoreactive
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neuronal cytoplasmic inclusions, Aβ plaques and amyloid
angiopathy, and hippocampal neurofibrillary degeneration, including extracellular tangles best seen with silver
stains.
Supportive neuropathological features of CTE
The group defined supportive pathological features for
CTE. These features were commonly found in the CTE
cases in addition to the required criteria, but were not considered diagnostic in isolation (Table 2).
Exclusions to the sole diagnosis of CTE
The presence of changes compatible with the diagnosis
of another neurodegenerative disease excludes CTE as a

Fig. 1  Low magnification inspection of p-tau-stained slides often revealed the irregular spatial pattern of CTE pathology. AT8-stained slides of
cerebral cortex in 3 cases of CTE showing irregular patches of p-tau pathology most dense at the depths of the sulci

Fig. 2  The microscopic features of the pathognomonic lesion of
CTE. The pathognomonic feature of CTE is a perivascular accumulation of p-tau aggregates in neurons, astrocytes and cell processes in
an irregular spatial pattern in the cerebral cortex and found preferentially at the depths of the sulci. a A large perivascular p-tau lesion
is found at the sulcal depths in a subject with CTE. b–f Multiple
perivascular foci are often found in the cortex in CTE. g The p-tau

aggregates in CTE include strikingly rounded structures in the neuropil that often are most dense in the areas surrounding the vessel. h
The rounded p-tau immunoreactive cell processes are more densely
distributed than those found in argyrophilic grain disease. All sections immunostained for AT8, bars indicate 100 µm, except in g and
h where the small bars indicate 10 µm
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Fig. 3  Hippocampal pathology in CTE. Examples of hippocampal
pathology in 2 cases of CTE of moderate severity. In example 1 (a–f),
there is a mild hippocampal atrophy, b mild neuronal loss in CA1,
c sparse NFTs in CA1, Bielschowsky silver stain, d sparse NFTs in
CA1, AT8 immunostain, e moderate numbers of diffusely immunopositive AT8 stained neurons in CA4, and f occasional AT8 immunopo-

sitive NFTs in the dentate gyrus. In example 2 (g–l), there is g more
severe hippocampal atrophy, h clear neuronal loss in CA1, i moderate density of NFTs in CA1, Bielschowsky silver stain, j moderate
density of NFTs in CA1, AT8 immunostain, k high numbers of AT8stained neurons and NFTs in CA4, and l moderate numbers of AT8
immunopositive NFTs in the dentate gyrus. Bars indicate 100 µm

single diagnosis, and indicates the presence of co-morbid
pathology. These features include CA1-predominant neurofibrillary degeneration in the hippocampus in association
with Aβ plaques consistent with AD [34]; prominent cerebellar dentate nucleus cell loss, coiled bodies in oligodendroglia, and tufted astrocytes as seen in PSP [25]; severe
involvement of the striatum and pallidum with extensive
astrocytic plaques in cortical and subcortical structures as
seen in CBD [21] or globular astrocytic inclusions of globular glial tauopathy [1].

Discussion
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The consensus panel of neuropathologists found that
the p-tau pathology of CTE is clearly distinct from other
tauopathies. The panel concluded that there is a pathognomonic lesion of CTE that consists of an accumulation of
abnormal tau in neurons and astroglia distributed around
small blood vessels at the depths of sulci in the cortex in
an irregular spatial pattern. Other supportive features of
CTE include abnormal p-tau immunoreactive pretangles

Acta Neuropathol (2016) 131:75–86
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Fig. 4  pTDP-43 pathology in CTE. a pTDP-43 neuronal inclusions
in the amygdala. b p-TDP-43 inclusions and dot-like neurites in CA1.
c p-TDP-43 dot-like neurites in entorhinal cortex. d pTDP-43 inclu-

sions and dot-like neurites in the dentate granule cell layer. All sections immunostained for p-TDP-43, bars indicate 100 µm

Table 2  Preliminary NINDS criteria for the pathological diagnosis of CTE
Required for diagnosis of CTE
1. The pathognomonic lesion consists of p-tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern
at the depths of the cortical sulci
Supportive neuropathological features of CTE
p-Tau-related pathologies:
1. Abnormal p-tau immunoreactive pretangles and NFTs preferentially affecting superficial layers (layers II–III), in contrast to layers III and
V as in AD
2. In the hippocampus, pretangles, NFTs or extracellular tangles preferentially affecting CA2 and pretangles and prominent proximal dendritic
swellings in CA4. These regional p-tau pathologies differ from the preferential involvement of CA1 and subiculum found in AD (Fig. 3)
3. Abnormal p-tau immunoreactive neuronal and astrocytic aggregates in subcortical nuclei, including the mammillary bodies and other hypothalamic nuclei, amygdala, nucleus accumbens, thalamus, midbrain tegmentum, and isodendritic core (nucleus basalis of Meynert, raphe
nuclei, substantia nigra and locus coeruleus)
4. p-Tau immunoreactive thorny astrocytes at the glial limitans most commonly found in the subpial and periventricular regions
5. p-Tau immunoreactive large grain-like and dot-like structures (in addition to some threadlike neurites) (Fig. 2h)
Non-p-tau-related pathologies:
1. Macroscopic features: disproportionate dilatation of the third ventricle, septal abnormalities, mammillary body atrophy, and contusions or
other signs of previous traumatic injury
2. TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus, anteromedial temporal cortex and
amygdala (Fig. 4)
Age-related p-tau astrogliopathy that may be present; non-diagnostic and non-supportive [22]
1.
2.

Patches of thorn-shaped astrocytes in subcortical white matter
Subependymal, periventricular, and perivascular thorn-shaped astrocytes in the mediobasal regions

3.

Thorn-shaped astrocytes in amygdala or hippocampus [22]
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Fig. 5  Age-related p-tau astrogliopathy that may be present. a and
b. Subpial p-tau immunopositive astrocytes may be found at the glial
limitans in the sulcal depths but are non-specific and non-diagnostic
for CTE (asterisks). c However, p-tau immunopositive subpial astrocytes accompanied by perivascular foci of p-tau positive neurons and
astrocytes (arrowhead) at the depths of the sulci are diagnostic for
CTE. d and e p-Tau immunopositive astrocytes surrounding small

venules in the deep white matter of the temporal lobe are not diagnostic for CTE and are often found in association with aging [22].
f p-Tau positive astrocytes may also be found in the crests of the
white matter of the frontal and temporal lobes with aging and other
conditions that are not diagnostic for CTE [22]. All sections immunostained for AT8, bars indicate 100 µm

and NFTs preferentially affecting superficial layers (layers
II–III), pretangles, NFTs or extracellular tangles primarily
in CA2 and CA4 of the hippocampus, NFTs in subcortical
nuclei, including the mammillary bodies and other hypothalamic nuclei, amygdala, nucleus accumbens, thalamus,
midbrain tegmentum, isodendritic core (nucleus basalis
of Meynert, raphe nuclei, substantia nigra and locus coeruleus), p-tau immunoreactive thorned astrocytes at the glial
limitans in the subpial and periventricular regions, p-tau
immunoreactive large grain-like and dot-like structures,
and TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus, anteromedial temporal cortex and amygdala. While this was only the
first meeting to address the neuropathological diagnosis of
CTE, and more research is needed to determine the nature
and degree of brain injury necessary to cause this neurodegeneration, the panel members also noted that the pathognomonic lesion of CTE has, thus far, only been found in
individuals who were exposed to brain trauma, typically
multiple episodes.
The panel also determined that the pathognomonic
lesion of CTE is distinct from age-related tau astrogliopathy (ARTAG), a morphological spectrum of astroglial
pathology detected by p-tau immunohistochemistry that
may coexist in the same brain with other disorders and is of
unclear etiology (Fig. 5). P-tau-immunoreactive astrocytes
in ARTAG include thorn-shaped astrocytes in the subpial,

subependymal, and perivascular regions of the white and
gray matter (Kovacs, in press). Changes of ARTAG may
be present in CTE, but in isolation, are non-specific and
non-diagnostic.
Although 9 of the 10 subjects diagnosed with CTE in
this study were former American football players and only
one was a former professional boxer, previous data has
shown that the pathological features of CTE associated
with boxing (often referred to as “dementia pugilistica”)
are similar to the pathological features of CTE associated
with football [28, 32]. Furthermore, the cortical areas most
likely to show early focal CTE pathology in boxers are
similar to American football players. While initial reports
of boxers with CTE described cerebellar scarring, atrophy
and loss of Purkinje cells [5], recent studies of pugilists
find that cerebellar pathology is rare aside from p-tau NFTs
and neurites in the dentate nucleus, Purkinje cells and roof
of the 4th ventricle [28, 32].
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Future directions
Using criteria from this consensus meeting, Bieniek and
colleagues reviewed the clinical records and brains of 1721
cases donated to the Mayo Clinic Brain Bank over the
past 18 years, and found CTE pathology in 32 % of contact sport athletes [2]. No cases of CTE were found in 162
control brains without a history of brain trauma or in 33
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Table 3  Recommended brain regions to be sampled and evaluated
Region

CTE

Middle frontal gyrus*
Superior and middle temporal gyri*
Inferior parietal lobule*
Hippocampus and entorhinal cortex
Amygdala
Thalamus
Basal ganglia with basal nucleus of Meynert
Midbrain including substantia nigra
Pons including locus coeruleus
Medulla including dorsal motor nucleus of
vagus

pTaua pTDP-43 Aβc
pTaua
pTaua
Aβc
b
pTau pTDP-43 Aβc
pTau pTDP-43b
pTau
pTau
pTau
pTau
pTau

Cerebellar cortex and dentate nucleus
Additional sections if high suspicion
Superior frontal gyrus
Temporal pole

pTau
pTaud
pTaud pTDP-43

Hypothalamus including mammillary body pTaud
In addition to the NIA-AA recommended regions for the evaluation
of Alzheimer’s disease (AD) neuropathologic change and Lewy body
disease (LBD) [34], we recommend wider p-tau screening to capture
CTE and other tauopathies. In addition, if there is a high index of suspicion of CTE, we recommend taking extra sections of frontal and
temporal cortices, and hypothalamus including the mammillary body
Bilateral representative sections from each region are recommended
if both cerebral hemispheres are available for microscopic analysis
* Most valuable for detecting CTE neuropathology
a

AT8 or equivalent Tau (CP-13 or PHF-1) on all cortical sections, if
positive: stain other areas and possibly sample additional areasd. We
do not recommend thioflavin or silver stains for the detection of CTE
lesions
b
TDP-43: amygdala and hippocampus, if positive then temporal pole
and frontal cortex
c
Aβ: middle frontal gyrus, inferior parietal lobule and hippocampus
and entorhinal cortex; if positive wider sampling is recommended
d

If there is a high index of suspicion consider taking extra sections,
specifically superior frontal gyrus, temporal pole, and hypothalamus
including mammillary body

cases with a history of a single traumatic brain injury. Of
the 21 with CTE pathology, 19 had participated in football
or boxing, and many were multiple sport athletes including rugby, wrestling, basketball, and baseball. One athlete
played only baseball, and another athlete only played basketball. Similarly, Ling and colleagues screened 268 cases
of neurodegenerative disease and controls in the Queen
Square Brain Bank for Neurological Disorders using the
preliminary McKee criteria [32] and found changes of CTE
in 11.9 % of neurodegenerative disorders and 12.8 % of
elderly controls. Of the cases with changes of CTE, 93.8 %
had a history of TBIs, 34 % had participated in high-risk
sports including rugby, soccer, cricket, lacrosse, judo and
squash, and 18.8 % were military veterans [24]. However,

it is unclear if all the cases with CTE changes described by
Ling and colleagues would have met strict criteria for CTE
using these newly defined NINDS guidelines. Furthermore,
the relationship between non-diagnostic, non-specific astrocytic p-tau pathology and a history of traumatic exposure
remains to be determined (Kovacs, in press).
At the present time, CTE remains a diagnosis that can
only be made definitively upon neuropathological examination of the brain. Because the pathological diagnosis
requires p-tau immunohistochemistry and the lesions are
irregularly distributed, the detection of CTE in autopsy
cohorts may require additional sampling compared to routine practices. The consensus panel’s minimum recommended sampling for CTE is found in Table 3. Sampling
follows the protocol recommended by Alzheimer Disease
Centers (National Institute on Aging-Alzheimer’s Association (NIA-AA) [34]) with the further recommendation that
all cortical sections be taken to include the region at the
depths of the cortical sulci. This has been shown in pilot
studies to detect 80 % of CTE cases; however, 20 % of
CTE cases, all early stage, would be missed by this sampling scheme [9]. Of the NIA-AA sampling guidelines, the
following blocks are most valuable for detecting CTE: sulcal depths of the superior and middle frontal gyrus, superior and middle temporal gyrus and inferior parietal gyrus
(Fig. 6). Of note, the Bielschowsky silver stain does not
always detect the diagnostically significant focal perivascular cortical tau lesions, and the panel recommended p-tau
immunohistochemistry for the diagnosis of CTE using AT8
immunostaining or equivalent p-tau antibody (CP-13 or
PHF-1). The question of how extensive the sampling must
be to “rule out” CTE was discussed, but no data were available to make this determination.
These criteria are the beginning of the process to fully
characterize the pathology of CTE, and this is only the first
of a series of consensus conferences on the subject funded
by the U01 NINDS research initiative. Many important questions were not addressed in this first consensus panel, including the degree of neuronal cell loss, gliosis, inflammation,
and hemosiderin deposition, and the diagnosis of CTE in
the presence of comorbid pathologies, including AD. Future
directions will include further validation of the neuropathological criteria for CTE, including staging of the severity of
p-tau pathology and characterization of early disease. More
pathological characterization will also be necessary to delineate the involvement of the other subcortical regions, including
amygdala, globus pallidus, subthalamic nucleus, accumbens,
neostriatum, thalamus, midbrain, cerebellum, spinal cord and
white matter. It will also be important to determine the differential hippocampal p-tau pathology in CTE compared to AD,
whether the TDP-43 pathology is distinctive for CTE and the
contribution of hippocampal sclerosis and TDP-43 deposition
to the clinical and pathological features. Population isolates
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Fig. 6  Minimum recommended brain regions for evaluation for CTE.
The following sections from the NIA-AA blocking scheme are recommended for p-tau immunostaining in evaluation for CTE (blue rectangles). In the cortical sections (blocks 1–5, 12, 13), the depths of
the cortical sulci should be included in the section. 1 Middle frontal
gyrus, 2 superior and middle temporal gyri, 3 inferior parietal lobule,
4 hippocampus, 5 amygdala and entorhinal cortex, 6 basal ganglia at

level of anterior commissure with basal nucleus of Meynert, 7 thalamus, 8 midbrain with substantia nigra, 9 pons with locus coeruleus,
10 medulla oblongata, 11 cerebellar cortex and dentate nucleus; additional sections if high suspicion of CTE (red rectangles): 12 superior
frontal gyrus, 13 temporal pole, 14 hypothalamus and mammillary
body

that develop unusual p-tau pathologies will need to be distinguished from CTE pathology in addition to Guam, such as
the Kii peninsula of Japan [23]. In addition, the contributions
of other proteinopathies, including β-amyloidosis (diffuse and
dense core Aβ plaques and amyloid angiopathy) and alphasynuclein will be important to determine. Similarly, the role
of microvascular pathology, iron deposition, axonal injury,
neuroinflammation and astrocytosis to the pathogenesis of
CTE pathology needs resolution.
Future investigation will be needed to understand the relationship of the pathology to the clinical symptoms, genetics,
neuroimaging and other biomarkers (including p-tau positron emission tomography (PET) imaging and cerebrospinal
fluid (CSF) and blood biomarkers), metabolomics, proteomics, and epigenetics. It will also be important to determine
whether specific “tau strains” are involved in the development of CTE. Furthermore, more information is needed
regarding the frequency, severity, and nature of the traumatic
exposures, length of survival after trauma, as well as factors
such as the age at first and last exposure to trauma, and the
effects of military compared to civilian brain trauma.
The limitations of the present study include the relatively small sample set, the use of digitized images, the
selection of suspected CTE cases by a single source, the
use of representative cases of moderate-to-late stage severity of CTE, and presence of some age-related co-morbidities. However, these limitations are offset by the fact that
all evaluating neuropathologists were evaluating the exact

same digital images, the cases were all uniformly prepared
by a central laboratory, and the evaluation was performed
blinded to all clinical or demographical data and gross neuropathological findings. Other limitations to the present
study include the lack of data regarding TBI history in the
non-CTE cases under evaluation. Future studies are being
designed to specifically address the contribution of TBI at
all levels of severity to neurodegenerative pathologies.

13

Conclusion
A consensus panel of 7 neuropathologists blinded to all
clinical conditions and demographics evaluated the identical
digitized images of 25 cases representing various tauopathies and concluded that the pathology of CTE is distinct
from other tauopathies. In addition, the panel described the
pathognomonic lesion of CTE as an accumulation of abnormal tau in neurons and astroglia distributed perivascularly
at the depths of sulci in the isocortex in an irregular pattern.
Future consensus meetings will address validation of the criteria among a wider group of neuropathologists using cases
submitted from multiple sources. In addition, future meetings will address the identification of comorbid CTE when
other neurodegenerative diseases and other diseases are present. Furthermore, additional research will be necessary to
determine the contribution of p-tau and other pathologies to
the development of clinical symptoms of CTE.

Acta Neuropathol (2016) 131:75–86

The incidence and prevalence of CTE remain unknown
and will likely require methods of in vivo detection and
diagnosis to make a clear determination. This first consensus conference on the pathological criteria for CTE
represents the first step along the path to standardizing
the neuropathology of CTE and paving the way for future
determinations of specific clinical symptomatology and
refinements in clinical diagnosis.
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